CRSP
CRISPR Therapeutics AG
Company · XNAS · US · USD
Market price
$55.35
+$1.37 (+2.54%) · 3 months
| Date and time | Price |
|---|---|
| Jun 25, 2026 | $53.98 |
| Jun 26, 2026 | $54.92 |
| Jun 29, 2026 | $56.35 |
| Jun 30, 2026 | $54.54 |
| Jul 1, 2026 | $55.62 |
| Jul 2, 2026 | $60.08 |
| Jul 6, 2026 | $61.89 |
| Jul 7, 2026 | $60.77 |
| Jul 8, 2026 | $59.20 |
| Jul 9, 2026 | $56.34 |
| Jul 10, 2026 | $53.35 |
| Jul 13, 2026 | $50.63 |
| Jul 14, 2026 | $50.46 |
| Jul 15, 2026 | $51.37 |
| Jul 16, 2026 | $48.57 |
| Jul 17, 2026 | $47.78 |
| Jul 20, 2026 | $46.99 |
| Jul 21, 2026 | $48.15 |
| Jul 22, 2026 | $47.24 |
| Jul 23, 2026 | $47.53 |
| Jul 24, 2026 | $46.54 |
| Jul 27, 2026 | $46.73 |
| Jul 28, 2026 | $47.55 |
| Jul 29, 2026 | $47.64 |
| Jul 30, 2026 | $48.44 |
| Jul 31, 2026 | $47.99 |
| Aug 3, 2026 | $49.57 |
| Aug 4, 2026 | $53.07 |
| Aug 5, 2026 | $52.45 |
| Aug 6, 2026 | $51.64 |
| Aug 7, 2026 | $53.52 |
| Aug 10, 2026 | $53.51 |
| Aug 11, 2026 | $54.07 |
| Aug 12, 2026 | $53.99 |
| Aug 13, 2026 | $53.99 |
| Aug 14, 2026 | $53.55 |
| Aug 17, 2026 | $54.28 |
| Aug 18, 2026 | $52.97 |
| Aug 19, 2026 | $59.81 |
| Aug 20, 2026 | $58.12 |
| Aug 21, 2026 | $59.50 |
| Aug 24, 2026 | $57.08 |
| Aug 25, 2026 | $60.90 |
| Aug 26, 2026 | $59.23 |
| Aug 27, 2026 | $59.37 |
| Aug 28, 2026 | $57.72 |
| Aug 31, 2026 | $56.98 |
| Sep 1, 2026 | $56.82 |
| Sep 2, 2026 | $56.92 |
| Sep 3, 2026 | $56.49 |
| Sep 4, 2026 | $55.79 |
| Sep 8, 2026 | $54.78 |
| Sep 9, 2026 | $53.45 |
| Sep 10, 2026 | $52.26 |
| Sep 11, 2026 | $51.72 |
| Sep 14, 2026 | $52.96 |
| Sep 15, 2026 | $51.83 |
| Sep 16, 2026 | $52.21 |
| Sep 17, 2026 | $57.33 |
| Sep 18, 2026 | $56.56 |
| Sep 21, 2026 | $58.33 |
| Sep 22, 2026 | $59.03 |
| Sep 23, 2026 | $55.76 |
| Sep 24, 2026 | $55.35 |
- Period change
- +2.54%
- Period low
- $46.54
- Period high
- $61.89
- Observations
- 64
- Updated
- Sep 24, 2026, 8:00 PM
About CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Company websiteClassifications
- Biotechnology · Biotech
- Pharmaceuticals · Pharma
- Healthcare
Market details
- Type
- Company
- Market
- XNAS
- Operating market
- XNAS
- Country
- US
- Currency
- USD
- Market capitalization
- $5,640,082,449.49
- Employees
- 393